Amgen Inc (AMGN) is an American biopharmaceutical company that discovers, develops, and markets human therapeutic drugs. Some of the company’s best-selling drugs include Neulasta/Neupogen, both of which are used to prevent infections in patients undergoing chemotherapy, and Enbrel, which fights rheumatoid arthritis and other autoimmune disease. Amgen was founded in 1980 and is headquartered in Thousand Oaks, California.

Currently, Amgen has a Zacks Rank #1 (Strong Buy), but it is subject to change following the release of the company’s latest earnings report. Here are 5 key statistics from this just announced report below.

Amgen:

1. Beat earnings estimates. The company posted $2.72, surpassing our Zacks Consensus Estimate of $2.38 (this number is excluding $0.28 from non-recurring items).

2. Beat revenue estimates. The company saw revenue figures of $5.723 billion, increasing 14% from the third quarter 2014, beating our estimate of $5.311 billion.

3. Generated $2.7 billion of free cash flow compared to $2.6 billion in the third quarter of 2014.
 
4. Chairman and CEO Robert A. Bradway said “We delivered record revenues, adjusted earnings and cash flow in the third quarter, while improving our operating margins and investing in six exciting new product launches.  With several innovative medicines still in development, we are well on the way to achieving our long-term objectives for shareholders and patients alike.”

5. AMGN was up/down $2.33, or 1.43%, to $165.00 as of 4:44 PM ET in after hours trading shortly after its earnings report was released.

Here’s a graph detailing Amgen’s recent quarterly revenue and growth rate:
 

Amgen Inc. (AMGN – Analyst Report) Recent Quarterly Revenue & Growth Rate | FindTheCompany